Now Reading: Biocon gets nod to sell Yesintek in 9 more markets
-
01
Biocon gets nod to sell Yesintek in 9 more markets
The Story in Brief
Biocon Ltd has secured market access for Yesintek, its proposed biosimilar to Stelara, in nine additional countries through a licence agreement with Janssen Sciences Ireland. The deal covers Australia, Brazil, China, Hong Kong, Israel, Mexico, New Zealand, South Korea and Kazakhstan with immediate effect.
The agreement builds on earlier settlements that gave Yesintek entry to the US, Europe, the UK, Canada and Japan. Stelara, owned by Johnson & Johnson's Janssen unit, had global sales of $6.08 billion in 2025. Biocon said the expanded access will offer an affordable treatment option for autoimmune diseases including Crohn's disease and plaque psoriasis. Product launches in each market remain subject to regulatory approval. Financial terms were not disclosed.
Indian Opinion Analysis
Both outlets deliver straight news coverage of Biocon's licence deal with Janssen, leading with the same facts: the nine new markets and the clinical details of Yesintek. Business Standard adds a caveat about regulatory approvals and notes financial terms were undisclosed, giving a slightly more cautious read, while CNBC-TV18 front-loads the share-movement angle in its headline but keeps the body purely factual. The difference is negligible, identical event, no slant divergence. The key open point is the absence of specific launch dates and regulatory filing status for the new markets, which will determine actual commercial impact. That awaits company disclosures.
Coverage: 2 sources, 2 neutral
Sources (2): cnbctv18.com (neutral report), business-standard.com (neutral report)
This brief was synthesised by AI from the 2 sources linked above, so one read covers every framing they carry. Methodology and corrections.
